Yuhan

Historical price data

Yuhan's mission is to develop innovative medicines that improve human and animal health, guided by its founder's revolutionary principle that corporate profits are a public trust. Its landmark achievement is the global success of 'Lecraza' (lazertinib), a third-generation EGFR-TKI for NSCLC, developed in partnership with Janssen, which has transformed it into a recognized oncology innovator. The company's strategy leverages deep internal R&D in small molecules, biologics, and drug delivery, amplified by a proactive open innovation model to in-license and co-develop high-potential candidates. This approach, combined with its robust commercial infrastructure, positions Yuhan for sustained growth across Asia and global markets.

Yuhan leverages a multi-modal R&D engine combining deep small molecule chemistry, a proprietary next-generation Antibody-Drug Conjugate (ADC) platform focused on novel linker-payloads, and advanced drug delivery systems, all accelerated through a strategic open innovation model for in-licensing and co-development.

Yuhan competes directly with global oncology leaders like AstraZeneca in the EGFR inhibitor market and faces off against ADC pioneers like Daiichi Sankyo. Domestically, it vies with Korean giants Celltrion and Dong-A ST. Its competitive edge lies in its integrated R&D platforms, agile open innovation model, and powerful commercial foundation in Korea.